The US company surprised with its test data.
(Photo: dpa)
Frankfurt For a long time it looked as if there was comparatively little going on in the therapy of coronavirus infections, despite intensive research. But with the surprisingly positive test data that the US group Merck & Co. and its partner Ridgeback Biotherapeutics presented a few days ago for their active ingredient molnupiravir, a turning point is now for the first time.
According to experts, the new development from the USA could be the first drug that can reduce the danger of Covid 19 diseases on a relatively broad front. This is because it appears to be much more suitable for mass use than the previously available active ingredients, which all have to be administered as an infusion or injection.
US doctors like Gabor Kelen, head of emergency medicine at Johns Hopkins University in the US state of Maryland, see the drug alongside vaccines as a significant contribution to transforming Covid-19 from a deadly pandemic to a manageable endemic.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further